TP53 and cancer: The SFV-based vector is an attractive tool for cancer immunotherapy because of its oncolytic nature and ability to induce p53-independent apoptosis of tumor cells (21), which may facilitate uptake and presentation of tumor antigens from the apoptotic bodies by antigen-presenting cells, thus enhancing cancer immunogenicity (22, 23).